eFFECTOR Therapeutics, Inc. (NASDAQ: EFTRW) is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapeutics that modulate protein synthesis. The company’s research targets the eukaryotic initiation factor 4F (eIF4F) complex, a key regulator of mRNA translation implicated in the progression of cancer and certain rare genetic diseases.
Founded in 2016 and headquartered in San Diego, California, eFFECTOR Therapeutics emerged from academic insights into translational control pathways. Since its inception, the company has built a pipeline grounded in the biology of the eIF4F complex, advancing assets from preclinical research into early-stage human trials.
The company’s lead candidate, zotatifin (eFT226), is a first-in-class, selective inhibitor of the eIF4A helicase subunit. Zotatifin is under evaluation in Phase 1/2 studies for patients with advanced solid tumors and hematologic malignancies, both as monotherapy and in combination with established anticancer agents. Beyond zotatifin, eFFECTOR is advancing additional preclinical programs focused on other nodes of the mRNA translation machinery.
eFFECTOR Therapeutics conducts clinical trials across the United States and Europe and maintains collaborations with academic institutions and industry partners to support its programs. The company is led by President and Chief Executive Officer Michael S. Vasconcelles, alongside a management team experienced in oncology research and development.
AI Generated. May Contain Errors.
